Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005203947
Thu, 31.10.2024       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology Akribion Therapeutics GmbH financed by strong Venture Capital Consortium with pharma expertise BRAIN can receive up to EUR 92.3 million R&D and commercial milestone fees plus additional royalties in exchange for granti [ … ]
Technical analysis
To the publication
Thu, 31.10.2024       BRAIN Biotech AG
DE0005203947

NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. BRAIN Biotech AG signs exclusive pharma licensing ag [ … ]
Technical analysis
To the publication
Thu, 03.10.2024       BRAIN Biotech AG
DE0005203947

Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons Zwingenberg, Germany, October 03, 2024 – Professor Dr. Wiltrud Treffenfeldt has informed the Chairman and the other members of the Supervisory Board of the BRAIN Biotech AG that she wishes to resign from her position as an ordinary member of the Superv [ … ]
Technical analysis
To the publication
Fri, 20.09.2024       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech Immediate upfront payment of EUR 18.41 million Royalty monetization of an investigational compound, deucrictiban [ … ]
Technical analysis
To the publication
Fri, 20.09.2024       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech Immediate upfront payment of EUR 18.41 million Royalty monetization of an investigational compound, deucrictiban [ … ]
Technical analysis
To the publication
Fri, 20.09.2024       BRAIN Biotech AG
DE0005203947

NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   BRAIN Biotech AG concludes royalty monetization d [ … ]
Technical analysis
To the publication
Fri, 20.09.2024       BRAIN Biotech AG
DE0005203947

NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   BRAIN Biotech AG concludes royalty monetization d [ … ]
Technical analysis
To the publication
Thu, 29.08.2024       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year Cash on-hand at € 13 million Significantly improved operating cash-flow in the 9M Forecasting a sequentially strong BioProducts quarter in Q4 FY 23/24 August 29, 2024, Zwingenberg/Germany – BRAI [ … ]
Technical analysis
To the publication
Wed, 29.05.2024       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes Zwingenberg and Greifswald, May 29, 2024 – BRAIN Biotech AG and Enzymicals AG are pleased to announce that Dr. Erik de Vries will join BRAIN Biotech as Senior Business Development Director Enzymes as of June 1st, 2024. De Vries will continue [ … ]
Technical analysis
To the publication
Tue, 28.05.2024       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets  Major milestone payment from pharma-project of € 1.5 million received BioProducts business growth accelerated in Q2, further acceleration expected throughout H2 On-track to meet fiscal year end targets Significantly strengthened cash position Zwing [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 18.11.2024, Calendar Week 47, 323rd day of the year, 43 days remaining until EoY.